Recursion Pharmaceuticals, Inc. (RXRX) scores 32 out of 100 on boothcheck's 11-model valuation framework. Verdict: Strong Avoid The estimated fair value is $-16.81, representing a 80% margin of safety.
Analysis includes bear, base, and bull fair value targets using DCF, Graham, regression, and 8 other valuation models.